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Focal delivery of AAV2/1-transgenes Into the Rat Brain 
by Localized Ultrasound-induced BBB opening
Angelika Alonso1, Eileen Reinz2, Barbara Leuchs2, Jürgen Kleinschmidt2, Marc Fatar1, Bart Geers3, Ine Lentacker3, 
Michael G. Hennerici1, Stefaan C. de Smedt3 and Stephen Meairs1
Delivery of drugs and macromolecules to the central nervous system (CNS) is hindered by the blood–brain barrier (BBB). 
Several approaches have been used to overcome this hindrance to facilitate the treatment of various CNS diseases. We now 
present results showing that chimeric adeno-associated virus 2/1 (AAV2/1) particles containing the coding region for the LacZ 
gene are efficiently delivered into the rat brain upon intravenous (IV) administration after BBB opening by focused ultrasound 
in the presence of vascular acoustic resonators. We show that the transgene is correctly and efficiently expressed in cells 
located in the neighborhood of the insonated focus, especially in the vicinity of small vessels and capillaries. Histochemical 
LacZ staining allows the identification of large amounts of cells expressing the enzymatically active protein. Using double 
immunofluorescence (IF) with antibodies against tubulinIII and bacterial LacZ, we identified these cells to be mostly neurons. 
A small proportion of the transduced cells was recognized as glial cells, reacting positive in the IF with antibodies against 
astrocytic markers. These results demonstrate that our approach allows a very specific, localized, and efficient expression of 
intravenously administered transgenes in the brain of rats upon ultrasound-induced BBB opening.
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Introduction
Gene and drug delivery to the central nervous system (CNS) 
is delimitated through the blood–brain barrier (BBB).1,2 Both 
the transcellular and paracellular pathway are strictly con-
trolled by special cellular features, including a dense tight 
junctional network of the BBB endothelium and limited pinocy-
totic activity.1,2 To facilitate drug delivery, several approaches 
to overcome the BBB have been investigated. Recently, it has 
been demonstrated that focused ultrasound in combination 
with ultrasound contrast agents (UCA) can lead to a transient 
disruption of the BBB without relevant neuronal damage.3–6 
As an underlying molecular mechanism of ultrasonographic 
BBB opening, both a transient disintegration of tight junctional 
complexes7 and an increased caveolae-mediated transcellu-
lar transport have been discussed.8 By this means, macro-
molecules such as antibodies9 or plasmid DNA for nonviral 
gene therapy10 have successfully been delivered in rodents.
Gene-targeted therapeutic approaches provide a new 
hope for several neurological diseases including a variety of 
neurodegenerative disorders. Recent and ongoing clinical tri-
als investigate the therapeutic potential of gene delivery of 
neurotrophic factors in Parkinson’s disease11 and Alzheim-
er’s disease12 by intraparenchymal injection of adeno- 
associated viral vectors. Recombinant adeno-associated 
virus (rAAV) vectors have successfully been used for gene 
 transfer to various regions of the CNS with favorable vector 
characteristics.13,14 rAAV vectors proved to be nontoxic with 
low immune reaction compared with other viral vectors such 
as adenovirus.15 Furthermore, a stable long-term gene expres-
sion16 with high yield can be achieved. The cell tropism and 
regional transduction pattern of rAAV in the CNS depends on 
the serotype. Following direct injection into the CNS, the most 
commonly applied rAAV serotype 2 (rAAV2) has been shown 
to transduce mainly neurons, whereas rAAV4 transduction 
was only found in ependymal cells, and rAAV5 transduces 
both ependymal and neuronal cells.17 Cross-packaging of 
AAV inverted terminal repeats into capsids of another sero-
type allows further modifications of the cellular tropism in the 
absence of differences in cis-acting elements.18 Pseudotyped 
viruses with rAAV2 inverted terminal repeats showed high-
est transduction rates and widest distribution when packaged 
into capsids of AAV1 or AAV5 (rAAV2/1, rAAV2/5) compared 
with the nonchimeric rAAV 2/2.19
A broad clinical application in CNS diseases has been 
impeded so far as the intraparenchymal delivery using neu-
rosurgically placed catheters is associated with a high rate of 
peri- and postinterventional complications.11 Vascular deliv-
ery of rAAV to CNS neurons, however, has been ineffective 
so far as most AAV vectors do not cross the BBB. Recently, 
it has been shown that the AAV9 type may target neurons in 
rodents20 after intravascular administration. However, a high 
peripheral tropism together with a limited neuronal transduc-
tion and pre-existing neutralizing antibodies in nonhuman 
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primates21 will probably hinder the shift towards a human 
translation of intravascular AAV9 delivery. Moreover, the 
intravascular route of administration does not allow a focused 
vector delivery to predefined brain structures. 
The aim of our study was to facilitate rAAV gene transfer 
into the CNS after noninvasive application. For this purpose, 
we combined intravenous (IV) administration of the chimeric 
rAAV2/1 with ultrasonographic localized opening of the BBB 
in adult rats. We found evidence that transient BBB disrup-
tion by ultrasound in the presence of microbubbles allows 
rAAV2/1 entry into the CNS with subsequent transduction of 
neuronal cells.
Results
opening of the BBB
For BBB opening, one hemisphere of all rats was sonicated 
as shown in Figure 1a. To confirm a transient disruption of 
the BBB with the employed ultrasound parameters, two rats 
received a solution of UCA without viral vectors and under-
went magnetic resonance imaging at 9.4 Tesla about 30 min-
utes after insonation of the left hemisphere.
In coronal sections, contrast-enhanced T1-weighted 
images after application of gadolinium showed a slight 
extravasation of the magnetic resonance imaging contrast 
agent in the left hemisphere as demonstrated in Figure 1b. 
The linear contrast enhancement was most prominent in the 
near-focus cortical area, but extended to the underlying stria-
tum (see arrow). As gadolinium does not pass the intact BBB, 
these data substantiate the BBB opening.
β-galactosidase expression: histochemistry
To demonstrate a successful gene transfer, we analyzed 
the expression of LacZ 1 week after insonation in the pres-
ence of intravenously administered viral vectors. Histochemi-
cal analyses were performed to detect the distribution of 
β-galactosidase, the LacZ gene product, enzymatically.
A blue staining, produced by cleavage of X-gal by active 
β-galactosidase, was observed only in focal mostly corti-
cal areas of the insonated left hemisphere (Figure 2a,c,d), 
whereas the complete contralateral, noninsonated hemi-
sphere, was not stained (Figure 2b). Most β-gal–positive 
foci were located in close vicinity to blood vessels and 
capillaries as depicted in Figure 2a. In addition to near-
vascular β-galactosidase expressing cells in the brain paren-
chyma, we also found successfully transduced cells forming 
part of the vessel walls (see arrows). Higher magnification 
(F igure 2c,d) showed multiple spotted cells in the brain cor-
tex with intracellular β-galactosidase.
Immunofluorescence microscopy
To further substantiate these results, we performed immu-
nofluorescence (IF) microscopy with a monoclonal antibody 
against β-galactosidase from E. coli, allowing a differentiation 
between endogenous and transduced β-galactosidase. Tak-
ing advantage of the high sensitivity of IF staining, we could 
demonstrate a widespread expression of β-galactosidase 
in clusters of several hundred cells (Figure 3a). Most of 
these clusters encircled a central blood vessel as shown in 
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Figure 1 experimental set-up and verification of BBB opening. (a) One hemisphere of male Wistar rats was insonated with a 500 kHz 
transducer adapted to a stereotactic positioning system. The transducer was driven by a function/arbitrary waveform generator and 
 amplifier. (b) To demonstrate successful opening of the BBB, rats underwent magnetic resonance imaging 30 minutes after insonation. 
Gadolinium-enhanced T1-weighted images showed a slight contrast enhancement in the focus of the insonation site (see arrow).
a b
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Figure 2 histochemical demonstration of β-galactosidase 
in transfected cells. One week after insonation, histochemistry 
for detection of the enzymatic activity of the β-galactosidase pro-
tein was performed to demonstrate the correct processing of the 
protein product. The (a, c, d) resulting blue X-gal staining product 
could be detected in mostly cortically located spots of the insonat-
ed hemisphere, partially in close proximity to capillaries or in cells 
forming part of the vessel wall (a, see arrows). In contrast, (b) no 
β-galactosidase activity was observed in the noninsonated hemi-
sphere. Magnifications were: a, b, ×50; c, ×200; d, ×400.
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F igure 3b. Comparable to the histochemical results, most of 
the cells of the capillary wall also stained positive for bacte-
rial β-galactosidase (Figure 3b). A high density of success-
fully transduced cell could further be located in proximity 
to the leptomeningeal cortical surface as demonstrated in 
Figure 3c. Overall, β-galactosidase positive reaction prod-
ucts were limited to a restricted mainly cortical area of the 
left hemisphere. At higher magnification, we noticed two dif-
ferent staining patterns in β-galactosidase expressing cells. 
A scattered and punctuate staining pattern was observed in 
a widespread area whereas some cells displayed a dense 
homogenous staining pattern excluding the nucleus (Figure 
3d,e). Most β-gal–positive cells exhibited an oval-shaped 
morphology and differed only little in terms of size and 
shape.
The contralateral hemisphere showed no expression of bac-
terial β-galactosidase, indicating that successful gene trans-
fer only occurred in the insonated hemisphere (Figure 3f).
To further characterize the transduced cell types, we 
performed double-IF microscopy with antibodies against 
β-galactosidase and cellular marker proteins. Double immu-
nolabeling with antibodies against the neuronal marker 
tubulinIII showed that the vast majority of β-galactosidase 
expressing cells stained positive for tubulinIII as seen in the 
overlay in Figure 4c. DAPI (4′,6′-diamidino-2-phenylindole 
hydrochloride) staining of the neuronal nuclei confirmed the 
a b c
d e f
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Figure 3 Immunofluorescence microscopy of β-galactosidase expression. To differentiate between endogenous and transduced 
β-galactosidase expression, immunofluorescence with antibodies specific against the bacterial β-galactosidase (coupled to Alexa-488, 
green) was performed. At lower magnification, (a–c) clusters of up to several hundred β-galactosidase expressing cells could be detected 
(magnification ×200), some of them centered around (b) capillaries or small vessels or (c) at the cortical surface. (d, e) At higher magnifica-
tion (magnification ×630), a widespread punctuate staining pattern together with a more homogenous staining of the whole cytoplasm of 
transduced cells was observed. (f) The contralateral noninsonated hemisphere did not show any β-galactosidase expression.
a b c20.00 µm
Figure 4 double immunofluorescence with antibodies against tubulinIII. To specify the transduced cell types, (a) double immu-
nolabeling with antibodies against β-galactosidase (coupled to Alexa-488, green) and (b) against the neuronal marker protein tubulinIII 
(coupled to Alexa-594, red) was performed. (c) Merge picture shows that almost all β-galactosidase expression occurs in cells staining 
positive for tubulinIII (see arrows), indicating that most of the transduced cells are neurons.
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strictly cytoplasmic β-gal expression in neurons. These find-
ings are in accordance with previous data on rAAV2/1 cell 
tropism,19 showing that almost exclusively neurons were suc-
cessfully transduced.
To demonstrate whether glial cells also were transduced 
by the recombinant particles, double immunoflorescence 
was performed using antibodies against the GFAP protein, 
known to be a specific astroglial marker protein. As shown in 
Figure 5, a small proportion of the GFAP-positive cells also 
stained for β-galactosidase, thus demonstrating that astro-
cytes were also transduced.
Quantification of transduction rate
As described above, IF microscopy was used to quantify 
expression rate in transduced cells. In a first set of experi-
ments, the percentage of cells positive for β-gal expression 
was calculated. As shown in Figure 6a, the amount of positive 
cells varied between the different animals analyzed. In most 
of the cases, a large proportion up to 90% of the cells stained 
positive for β-galactosidase in the insonated hemisphere, 
whereas in three animals, the transduction rates were lower 
(1L–8L). No significant staining was observed in the contral-
ateral hemisphere (1R–8R). In the control animals without 
injected viral particles, no staining at all was detected (data 
not shown). Corresponding to these results, quantification of 
the total staining intensity in the second set of experiments 
(Figure 6b) showed high sum intensities in the insonated 
hemispheres of the animals (1L–8L) whereas IV administra-
tion of recombinant viral particles without insonation did not 
lead to relevant intensity values (1R–8R). Thus, these results 
indicate that a large proportion of the cells can be targeted 
by the recombinants viruses, being most of them identified 
as neurons.
discussion
Gene therapy is a promising new strategy for the treatment 
of various CNS diseases. However, the delivery of vector 
genomes to the brain is hampered by the intact BBB, sepa-
rating the vascular compartment from the brain parenchyma. 
Our study now demonstrates that ultrasound-induced BBB 
opening in combination with IV AAV2/1 vectors (i) facilitates 
the entry of the viral vectors in the CNS, (ii) leads to an effi-
cient and focal transduction in the sonicated regions, and (iii) 
targets mainly neuronal cells.
a b c20.00 µm 20.00 µm 20.00 µm
Figure 5 double immunofluorescence with antibodies against GFAP. To evaluate the transduction of nonneuronal glial cells, 
(a) c olocalization of β-galactosidase (coupled to Alexa-488, green) and (b) the astrocytic marker protein GFAP (coupled to Alexa-594, 
red) was investigated. (c) As shown in the merge picture, one GFAP-positive cell displays a β-galactosidase staining (see small arrows), 
whereas other astrocytes do not show a colocalization with β-galactosidase (see big arrow). These data demonstrate that a small fraction 
of transduced cells belong to the astrocytic cell line.
100
90
80
70
%
 P
o
si
tiv
e
 c
e
lls
/O
F
60
50
40
30
20
10
0 0
1,000,000
2,000,000
3,000,000
Su
m
 o
f i
nt
en
sit
ie
s 
(pi
xe
l)
4,000,000
5,000,000
6,000,000
1L 2L 3L 4L 5L 6L 7L 8L
Rat no.
1R 2R 3R 4R 5R 6R 7R 8R 1L 2L 3L 4L 5L 6L 7L 8L
Rat no.
1R 2R 3R 4R 5R 6R 7R 8R
a b
Figure 6 Quantification of β-galactosidase expression. (a) To evaluate the number of successfully transduced cells, all β-galactosidase 
expressing cells per optical field (OF) were counted. At least ten OFs per animal and hemisphere were considered (L, left hemisphere; 
R, right hemisphere). (b) Likewise, the sum of intensities defined as number of positive pixels per OF was quantified for both the insonated 
left hemisphere and the noninsonated right hemisphere. Values for control animals without administration of recombinant viral particles 
were omitted because we never found any positive reacting cells in these animals.
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Recombinant adeno-associated viral vectors are counted 
among the most commonly used viral vector systems for 
gene delivery. AAV vectors offer several advantages com-
pared with other vector systems including low immunogenic-
ity and mediation of a high-level and long-term expression. 
With the characterization of different serotypes displaying 
different cell tropisms, a more specific transduction of cell 
types could be realized (for a review, see ref. 22). The limited 
transgene capacity of about 5 kb, often pointed out as a main 
disadvantage of AAV vector systems, has significantly been 
enhanced by usage of short promoters and transcriptional 
control elements.23
The flexibility of AAV-based vector systems has led to a 
broad interest in clinical applications. To date, several Phase I 
studies of degenerative CNS diseases have been completed 
or are still ongoing with promising results.11,12 In patients with 
advanced Parkinson’s disease, gene transfer of glutamic 
acid decarboxylase was successfully achieved by stereot-
actic injection of rAAV2-glutamic acid decarboxylase in the 
subthalamic nucleus.11 However, the initial enthusiasm was 
trimmed back due to a high percentage of periprocedural 
complications of direct CNS injections.
To avoid invasive application methods, new strategies to 
overcome the BBB are needed. Recently, several studies 
have highlighted the ability of the AAV serotype 9 to cross 
the intact BBB, probably by active transport mechanisms. In 
rodents, intravascular delivery of rAAV9 led to a long-lasting 
transduction of neurons and glial cells throughout the whole 
brain.20 However, in nonhuman primates, a shift in the cell 
tropism towards a predominant transduction of glial cells was 
observed.21 Moreover, a translation into a clinical application 
is hindered by pre-existing neutralizing antibodies and a high 
peripheral tropism.21 Even disregarding these limitations, it 
has to be considered that gene therapy with AAV9 will always 
lead to an overflow with AAV9 of the whole CNS: as this sero-
type will cross the BBB spontaneously after IV administra-
tion, the expression of the transgene cannot be limited to the 
region of interest. For the most CNS diseases like tumors, 
stroke or basal ganglia diseases like Parkinson’s disease or 
Huntington’s disease, a transduction of the whole CNS is nei-
ther necessary nor desirable. In these cases, a precisely local-
ized gene delivery into the target region would be of utmost 
interest. In the last few years, focused ultrasound in the pres-
ence of gas-filled microbubbles has been shown to promote 
a focal and reversible BBB opening.24 Depending on various 
sonication parameters like acoustic pressure or microbubble 
concentration, optimized protocols with avoidance of cell 
and tissue damage have been worked out.6 Several pre-
clinical animal studies using ultrasound-induced BBB open-
ing have been conducted with a focus on neurooncology,25 
indicating effective delivery of chemotherapeutics. The exact 
entry mechanism into the CNS is yet under investigation, but 
experimental studies point at diffusion through the paracel-
lular route following transient disintegration of tight junctions26 
and increased caveolae-mediated transport.8
In our experiments, histochemical detection of a blue stain-
ing, produced by cleavage of X-gal, proved the success-
ful transduction of neuronal cells with expression of active 
β-galactosidase. Transduction of cells with AAV requires not 
only overcoming the BBB but also uptake of the viral particles 
via endocytosis with endosomal acidification, enhancing their 
phospholipase activity.27 Our results therefore support previ-
ous hypotheses, suggesting that drug delivery into target cells 
by ultrasound in combination with microbubbles results mainly 
from enhanced endocytosis.10,28 Consistent with this conclusion, 
we could demonstrate in a previous in vitro study that modifica-
tion of rAAV particles by PEGylation impedes successful trans-
duction, possibly by impaired interaction with cell membrane 
receptors needed for receptor mediated endocytosis.29
Quantification of the transduction rates showed a large 
amount of transgene expression strictly limited to the soni-
cated regions. The transduction efficiency is a major advan-
tage in the usage of viral gene transfer compared with the 
naked plasmid DNA. Huang and colleagues10 investigated 
the targeted delivery of the exogenous gene pBDNF-EGFP 
by focused ultrasound and microbubbles in 4-week-old mice. 
They found that enhanced green fluorescent protein expres-
sion was limited to the cytoplasm of only some neurons at the 
sonicated regions. Consequently, most clinical gene transfer 
studies have concentrated on viral vector strategies.
To specify the cell tropism of distinct rAAV serotypes, chi-
meric or pseudotyped vectors have recently been designed.19 
Genomes containing the terminal repeats of a commonly 
used serotype, mostly AAV2, can be packaged in capsids of 
another serotype, resulting in modifications of transduction 
distribution and efficiency. For our study, we constructed the 
chimeric rAAV2/1 which resulted in a widespread transduc-
tion of almost exclusively neurons in the sonicated regions. 
This observed pattern is consistent with previous studies, 
demonstrating that direct injection of rAAV2/1 in several brain 
structures of rats led to a higher number of transduced cells 
and a higher volume of distribution compared with the non-
chimeric rAAV2/2.
By choosing an appropriate promoter, both the cell tropism 
and the transduction efficiency can further be increased. In 
our experiments, we used the strong cytomegalovirus (CMV) 
immediate-early promoter as vectors containing the CMV 
promoter have been shown to almost exclusively transduce 
neurons.16 In addition, creation of hybrid form promoters30 and 
insertion of transcriptional control elements31 have recently 
led to optimized transduction efficiency.
To further target gene therapy vectors, cell type-specific 
binding ligands at the capsid surface have lately been inves-
tigated.32 Mueller and colleagues were the first to design ran-
dom AAV peptide libraries in which each virus particle exhibits 
a random peptide at the capsid surface. By this means, spe-
cific AAV vectors targeting endothelial cells33 as well as other 
cell lines or tissues have been selected.
Concluding, we could demonstrate for the first time the 
feasibility of a localized AAV gene transfer into the CNS by 
ultrasound-induced BBB opening. The numerous redevelop-
ments in vector engineering allow for very specific modeling 
of viral vectors, thus providing an encouraging new treatment 
strategy for CNS diseases.
Materials and methods
Vectors. The engineering of AAV vectors was conducted 
as described elsewhere.34 Briefly, vector production was 
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effected by cotransfection of vector plasmid pUF3nlsLacz35 
and helper plasmid pDP136 in 293T cells. The vector plasmid 
encodes for AAV2 terminal repeat elements and the trans-
gene nlsLAcZ (nuclear localization signal; β-galactosidase) 
driven by a CMV promoter. The helper plasmid enclosed an 
AAV1 cap. The titers of the vector preparation were 5.3 × 1011 
encapsidated vector genomes/ml.
Ultrasound device. For BBB opening, a 500 kHz transducer 
(H-104MR) was driven by a function generator (Agilent 
33120 A Function/Arbitrary Waveform Generator; Agilent 
Technologies, Santa Clara, CA) and amplifier (model 40AD1; 
AR Amplifier Research, Souderton, PA). The transducer was 
adjusted to a cone filled with deionized water and adapted 
to a stereotactic positioning system (Figure 1a). The distal 
cone aperture with a diameter of 5 mm was stereotactically 
concentrated on the left hemisphere, the contralateral hemi-
sphere was used as intraindividual control. The basic princi-
ples of focused ultrasound are described in supplementary 
Figure s1. The pressure amplitude was 2.2 MPa as mea-
sured by a calibrated 400 µm diameter hydrophone (HGL 
400; Onda, Sunnyvale, CA). Assuming a total pressure lost 
of 49% due to attenuation through the rat skull as described 
previously,9 the effective pressure amplitude was estimated 
at about 1.1 MPa. The burst count was 10 ms at a repetition 
frequency of 1 Hz.
Vascular acoustic resonators. The vascular acoustic reso-
nators (BR38) were kindly provided by Bracco Research, 
Plan-Les-Ouates. BR38 are gas-filled (fluorocarbon—air) 
vascular acoustic resonators with a lipidic shell, a number 
mean diameter of 1.4 µm and a volume mean diameter of 3.6 
µm. The concentration for a dispersion in saline was 0.2 × 109 
bubbles/ml.
Animal model. All animals were approved by the local gov-
ernment authorities in accordance with the animal protec-
tion guidelines. Fourteen male Wistar rats (Charles River, 
Sulzfeld, Germany) weighing 465 ± 48 g were anesthetized 
with 1.5% isofluorane, body temperature was controlled 
with a heating pad. The hair over the skull was removed 
with depilatory cream, and the tail vein was catheterized. 
All rats underwent insonation of the left hemisphere over 
40 seconds. Simultaneously, eight of these received 1.06 × 
1011 encapsidated vector genomes dispersed in a solution of 
UCA (BR38; Bracco Research, Princeton, NJ) at a concen-
tration of 0.1 ml/kg body weight via the tail vein catheter. Four 
further animals were insonated as described above, together 
with IV administration of UCA, but without administration of 
recombinant viral particles. Finally, two more rats received a 
solution of UCA without viral vectors instead and were used 
for approval of BBB opening by magnetic resonance imag-
ing (9.4 Tesla Bruker BioSpec 94/20 USR; Tesla, Karlsruhe, 
Germany).
All animals were killed after 7 days by transcardial perfu-
sion with 2% paraformaldehyde and 0.5% glutaraldehyde in 
deep anesthesia. Brains were removed and incubated in 2% 
paraformaldehyde and 0.5% glutaraldehyde at 4 °C over-
night, followed by incubation in sucrose 30% at 4 °C for 3 
hours. After freezing in ice-cold isopentan, the brains were 
stored at −80 °C until processing.
Immunohistochemistry. Coronal sections were cut at 10 µm 
on a freezing microtome (Leica CM 1900; Leica, Bensheim, 
Germany) and treated with 10 mmol/l TRIS–HCl at 98 °C 
for demasking. For detection of β-galactosidase, we used a 
β-Gal Staining Kit Cat. No. K1465-01, Invitrogen (Carlsbad, 
CA). Sections were rinsed in phosphate-buffered saline 1× 
and afterwards incubated in fixation solution for 10 minutes. 
After two washing steps in phosphate-buffered saline 1×, 
the sections were incubated for 48 hours in staining solution 
containing 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside 
(X-Gal) at 37 °C in a humidified incubator.
Immunofluorescence. Cryosections of 10 µm were treated 
with TBS-Triton 0.2% and afterwards incubated with a 
monoclonal antibody against β-galactosidase from E. coli 
(SM3002P; Acris Antibodies, Herford, Germany) overnight at 
37 °C. Sections were then washed in TBS-Triton 0.2% and 
afterwards incubated with a goat antimouse antibody coupled 
to Alexa Fluor 488 (1:800; Invitrogen). After washing in TBS-
Triton 0.2%, sections were mounted in antifading medium. 
Pictures were taken with a confocal microscope (Leica DM 
IRBE; Leica and Olympus FluoView FV1000; Olympus, 
Tokyo, Japan).
For double immunolabeling with antibodies against cellular 
marker proteins, the following primary and secondary anti-
bodies were used: α-β-Gal (monoclonal mouse, SM3002P; 
Acris), α-tubulinIII (polyclonal rabbit, ab18207; Abcam), 
α-GFAP (polyclonal rabbit, ab7260; Abcam), goat antimouse-
Alexa 488 (1:800; Invitrogen), goat antirabbit-Alexa 594 
(1:800; Invitrogen) and DAPI 100 ng/ml working solution.
Quantification of transduction rates. For quantification of 
transduction rates, the expression of β-galactosidase was 
analyzed using IF microscopy. Two different parameters were 
considered: the number of cells expressing β-galactosidase, 
irrespective of the intensity of such expression, and the total 
intensity per optical field of the β-galactosidase expression, 
irrespective of the number of cells transduced. Thus, number 
of transfected cells and intensity of expression were quanti-
fied independently. For this, serial sections of the brain were 
prepared and every second slice was viewed under the micro-
scope. Using a computer program, the section with the largest 
amount of pixels (taken as a measure of expression intensity) 
was identified. Pictures were taken from integrated images 
of this slice and analyzed as described.37 For quantification, 
two control groups were used: to evaluate the effect of IV 
administered recombinant viral particles without ultrasound-
induced BBB opening, the contralateral hemispheres of the 
eight insonated rats were always examined. A second control 
group were animals treated with ultrasound and microbubbles 
but without injection of viral recombinant particles. Quantifica-
tion was performed in a double-blinded form.
supplementary material
Figure s1. Schematic drawing demonstrating the principle 
of focused ultrasound-gene delivery. 
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